WO1985002862A1 - PRODUCTION D'INTERFERON alpha HUMAIN - Google Patents

PRODUCTION D'INTERFERON alpha HUMAIN Download PDF

Info

Publication number
WO1985002862A1
WO1985002862A1 PCT/AU1984/000263 AU8400263W WO8502862A1 WO 1985002862 A1 WO1985002862 A1 WO 1985002862A1 AU 8400263 W AU8400263 W AU 8400263W WO 8502862 A1 WO8502862 A1 WO 8502862A1
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
human interferon
nucleotide sequence
polypeptide
sequence
Prior art date
Application number
PCT/AU1984/000263
Other languages
English (en)
Inventor
Anthony William Linnane
Phillip Nagley
Sangkot Marzuki
Manfred Werner Beilharz
Ian Thomas Nisbet
Original Assignee
Monash University
Commonwealth Serum Laboratories Commission
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Commonwealth Serum Laboratories Commission filed Critical Monash University
Publication of WO1985002862A1 publication Critical patent/WO1985002862A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Une molécule d'ADN qui, lors de sa sécrétion, code pour un interféron alpha humain appelé IFN-alphaM1, comporte une séquence de nucléotides essentiellement semblable à celle montrée dans la figure 2. Sont également décrits une molécule d'ADN recombinant, un vecteur ou véhicule de clonage et une cellule hôte, contenant chacun cette séquence de nucléotide. Est également décrit un polypeptide possédant une activité d'interféron alpha humain, comportant une séquence d'acides aminés essentiellement semblable à celle montrée dans la figure 2.
PCT/AU1984/000263 1983-12-23 1984-12-20 PRODUCTION D'INTERFERON alpha HUMAIN WO1985002862A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU298283 1983-12-23
AUPG2982 1983-12-23

Publications (1)

Publication Number Publication Date
WO1985002862A1 true WO1985002862A1 (fr) 1985-07-04

Family

ID=3693481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1984/000263 WO1985002862A1 (fr) 1983-12-23 1984-12-20 PRODUCTION D'INTERFERON alpha HUMAIN

Country Status (2)

Country Link
EP (1) EP0165942A1 (fr)
WO (1) WO1985002862A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154186A3 (en) * 1984-02-10 1987-12-09 J.K. And Susie L. Wadley Research Institute And Blood Bank Isolation of a novel interferon gene and expression thereof
US5413908A (en) * 1984-11-12 1995-05-09 Lister Institute Of Preventive Medicine Method of characterizing genomic DNA by reference to a genetic variable
US5480956A (en) * 1989-06-29 1996-01-02 Toray Industries, Inc. Feline interferon and process for production thereof
EP1997900A2 (fr) 1996-04-05 2008-12-03 Novartis Vaccines and Diagnostics, Inc. Vecteurs à base d'alpha virus recombinants avec inhibition réduite de synthèse macromoléculaire cellulaire
EP2206785A1 (fr) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
EP2266602A2 (fr) 2004-11-01 2010-12-29 Novartis Vaccines and Diagnostics, Inc. Approches combinatoires destinées à produire des réponses immunitaires
EP2281832A2 (fr) 2000-07-05 2011-02-09 Novartis Vaccines and Diagnostics, Inc. Polynucléotides codant pour des polypeptides antigéniques du type C du VIH, de tels polypeptides et leurs utilisations
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
EP2339010A2 (fr) 2002-05-01 2011-06-29 Gbp Ip, Llc Particules de vecteur de lentivirus pour l'inactivation de complément
EP2412242A2 (fr) 2001-07-05 2012-02-01 Novartis Vaccines and Diagnostics, Inc. Polynucléotides codant pour des polypeptides antigènes de type C du VIH, polypeptides et leurs utilisations
US8486693B2 (en) 2006-05-23 2013-07-16 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2017040387A2 (fr) 2015-08-31 2017-03-09 Technovax, Inc. Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
WO2017180770A1 (fr) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Systèmes de réplicon d'artérivirus recombinant et utilisations correspondantes
EP3608401A1 (fr) 2012-07-05 2020-02-12 Ohio State Innovation Foundation Compositions et procédés liés aux vaccins viraux
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
US11364310B2 (en) 2016-10-17 2022-06-21 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7246281A (en) * 1980-07-01 1982-01-07 F. Hoffmann-La Roche Ag Interferons and process for their preparation
WO1983002460A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp INTERFERON 'alpha' 74
WO1983002457A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 76
WO1984000776A1 (fr) * 1982-08-18 1984-03-01 Cetus Corp Interferon-alpha 6l
WO1984003300A1 (fr) * 1983-02-24 1984-08-30 Inst Organicheskogo Sinteza Ak Interferon n humain leucocytaire et son procede d'obtention dans des cellules bacteriennes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7246281A (en) * 1980-07-01 1982-01-07 F. Hoffmann-La Roche Ag Interferons and process for their preparation
WO1983002460A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp INTERFERON 'alpha' 74
WO1983002457A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 76
WO1984000776A1 (fr) * 1982-08-18 1984-03-01 Cetus Corp Interferon-alpha 6l
WO1984003300A1 (fr) * 1983-02-24 1984-08-30 Inst Organicheskogo Sinteza Ak Interferon n humain leucocytaire et son procede d'obtention dans des cellules bacteriennes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Archives of Biochemistry and Biophysics, Volume 221, No. 1, issued 1983, February 15 (New York, U.S.A.), S. PESTKA, "Human Interferons - from Protein Purification and Sequence to Cloning and Expression in Bacteria: Before, Between, and Beyond", see page 16 figure 17, page 18 figure 18, and page 26 figure 26. *
Nature, Volume 290, issued 1981, March 5 (London, U.K.) D.V. GOEDDEL, "The Structure of Eight Distinct Cloned Human Leukocyte Interferon cDNAs", see pages 20-26. *
Philosophical Transactions of the Royal Society London, Series B, Volume 299, No. 1094, issued 1982, September 24, (London, U.K.), C. WEISSMANN et al, "Structure and Expression of Human IFN/OC Genes, see pages 7-28, particularly page 12. *
Science, Volume 212, issued 1981, June 5 (Washington, D.C. U.S.A.), R.M. LAWN et al, "DNA Sequences of Two Closely Linked Human Leukocyte Interferon Genes", see pages 1159-1162. *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154186A3 (en) * 1984-02-10 1987-12-09 J.K. And Susie L. Wadley Research Institute And Blood Bank Isolation of a novel interferon gene and expression thereof
US5413908A (en) * 1984-11-12 1995-05-09 Lister Institute Of Preventive Medicine Method of characterizing genomic DNA by reference to a genetic variable
US5480956A (en) * 1989-06-29 1996-01-02 Toray Industries, Inc. Feline interferon and process for production thereof
EP1997900A2 (fr) 1996-04-05 2008-12-03 Novartis Vaccines and Diagnostics, Inc. Vecteurs à base d'alpha virus recombinants avec inhibition réduite de synthèse macromoléculaire cellulaire
EP2298900A1 (fr) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladies intracellulaires
EP2206785A1 (fr) 1998-12-31 2010-07-14 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
EP2281832A2 (fr) 2000-07-05 2011-02-09 Novartis Vaccines and Diagnostics, Inc. Polynucléotides codant pour des polypeptides antigéniques du type C du VIH, de tels polypeptides et leurs utilisations
EP2311958A2 (fr) 2000-07-05 2011-04-20 Novartis Vaccines and Diagnostics, Inc. Polynucléotides codant pour des polypeptides antigéniques du type C du VIH, de tels polypeptides et leurs utilisations
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
EP2412242A2 (fr) 2001-07-05 2012-02-01 Novartis Vaccines and Diagnostics, Inc. Polynucléotides codant pour des polypeptides antigènes de type C du VIH, polypeptides et leurs utilisations
EP2339010A2 (fr) 2002-05-01 2011-06-29 Gbp Ip, Llc Particules de vecteur de lentivirus pour l'inactivation de complément
EP2266602A2 (fr) 2004-11-01 2010-12-29 Novartis Vaccines and Diagnostics, Inc. Approches combinatoires destinées à produire des réponses immunitaires
US8486693B2 (en) 2006-05-23 2013-07-16 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP3608401A1 (fr) 2012-07-05 2020-02-12 Ohio State Innovation Foundation Compositions et procédés liés aux vaccins viraux
WO2017040387A2 (fr) 2015-08-31 2017-03-09 Technovax, Inc. Vaccin à base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
US11555205B2 (en) 2016-04-13 2023-01-17 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2017180770A1 (fr) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Systèmes de réplicon d'artérivirus recombinant et utilisations correspondantes
US11364310B2 (en) 2016-10-17 2022-06-21 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11725194B2 (en) 2017-12-19 2023-08-15 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
US11826416B2 (en) 2018-01-19 2023-11-28 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems

Also Published As

Publication number Publication date
EP0165942A1 (fr) 1986-01-02

Similar Documents

Publication Publication Date Title
WO1985002862A1 (fr) PRODUCTION D'INTERFERON alpha HUMAIN
Goeddel et al. The structure of eight distinct cloned human leukocyte interferon cDNAs
Nagata et al. The structure of one of the eight or more distinct chromosomal genes for human interferon-α
Schmid et al. Induction of mRNA for a serine protease and a beta-thromboglobulin-like protein in mitogen-stimulated human leukocytes.
US5798228A (en) Recombinant production of dog and horse type I interferons
RU2092561C1 (ru) Способ получения полипептида со свойствами гамма-интерферона человека
EP0108128B1 (fr) (Met-1,des-Cys1,des-Tyr2,des-Cys3) interféron gamma humain et séquence d'ADN qui le code
CA1266628A (fr) Fabrication et expression de genes structuraux
EP0192811B1 (fr) Mutéines à base de protéines biologiquement actives épuisées en cystéine, leur préparation, compositions contenant ces mutéines et gènes structuraux, vecteurs et organismes propres à la préparation desdites mutéines et leur production
EP0041313B1 (fr) Séquences d'ADN, molécules d'ADN recombinant et procédé pour la production de l'interféron de fibroblaste humain
US5089400A (en) Polypeptides and process for the production thereof
US4751077A (en) Interferons with novel cysteine pattern
CA1339776C (fr) Interferon gamma de cheval
Leung et al. The structure and bacterial expression of three distinct bovine interferon-β genes
JPH0745516B2 (ja) ヒトγ―インターフェロン活性を有するポリペプチドおよびその製造法
US4761375A (en) Human interleukin-2 cDNA sequence
EP0095350A2 (fr) Un procédé pour la préparation d'un polypeptide semblable au gamma interféron humain
KR930000273B1 (ko) 약물의 유전공학적 제조방법
US4716217A (en) Hybrid lymphoblastoid-leukocyte human interferons
CN107286255A (zh) 一种由鸡白蛋白、鸡干扰素γ和鸡干扰素α组成的融合蛋白及其制备方法
Ivanov et al. Unusual effect of clusters of rare arginine (AGG) codons on the expression of human interferon α1 gene in Escherichia coli
US4734491A (en) DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
EP0174143B1 (fr) Famille distincte d'interférons de leucocytes humains, compositions les contenant, méthodes pour leur production et ADN et hôtes transfectés pour ces méthodes
CN107353347A (zh) 一种由猪白蛋白、猪干扰素γ和猪干扰素α组成的融合蛋白及其制备方法
EP0173935A1 (fr) Interférons humains d'hybrides de lymphoblastoides-leucocytes

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE